Sickle cell anemia is characterized by chronic hemolysis coupled with extensive vascular inflammation. This inflammatory state also mechanistically promotes a high risk of lethal, invasive pneumococcal infection. Current treatments to reduce vasoocclusive complications include chronic hydroxyurea therapy to induce fetal hemoglobin. Since hydroxyurea also reduces leukocytosis, an understanding of the impact of this treatment on pneumococcal pathogenesis is needed. Using a sickle cell mouse model of pneumococcal pneumonia and sepsis, administration of hydroxyurea was found to significantly improve survival. Hydroxyurea treatment decreased neutrophil extravasation into the infected lung coincident with significantly reduced levels of Eselectin in serum and on pulmonary epithelia. The protective effect of hydroxyurea was abrogated in mice deficient in E-selectin. The decrease in E-selectin levels was also evident in human sickle cell patients receiving hydroxyurea therapy. This data indicate that in addition to induction of fetal hemoglobin, hydroxyurea attenuates leukocyteendothelial interactions in SCA resulting in protection against lethal pneumococcal sepsis.
Introduction
Sickle cell anemia (SCA) is characterized by chronic hemolytic anemia and vascular inflammation. Hydroxyurea therapy decreases vaso-occlusive complications of sickle cell anemia and reduces mortality 1, 2 , but the mechanism of this benefit has been debated. Elevated white blood cell counts have been found to correlate with greater mortality in SCD 3 and early studies suggested hydroxyurea reduced leukocytosis 4, 5 .
Subsequent studies found no statistical association between reduction of leukocytosis and mortality in SCA patients receiving hydroxyurea, implicating increased levels of hemoglobin F (HbF) as the main predictor of mortality 6 . A recent placebo-controlled clinical trial of hydroxyurea in pediatric SCA patients confirmed a highly significant decrease in total white blood cell and absolute neutrophil counts following hydroxyurea treatment as well as increases in hemoglobin and HbF levels 7 . A significant decrease in acute chest syndrome, which is oftentimes initiated by lung infection, was also observed in this study 7 .
Bacteremia was recorded six times in the placebo group but only three times in the hydroxyurea-treated patients 7 , a trend that was not significant due to the low incidence. While induction of HbF is generally accepted to be a major benefit of hydroxyurea therapy in SCA, the relative contribution of other factors, including decreased white blood cell counts, to positive outcomes remains a possibility that has yet to be explored.
Modulation of leukocytosis by hydroxyurea raises the question of infection risk in
SCA. Children with SCA have a 400-fold greater risk of fulminant, lethal pneumococcal sepsis than their healthy peers or patients with other hemolytic anemias [8] [9] [10] , a finding recapitulated in the sickle cell mouse model 11 . Despite administration of penicillin
For personal use only. on October 28, 2017. by guest www.bloodjournal.org From prophylaxis, pneumococcal polysaccharide vaccine, and pneumococcal proteinconjugate vaccine, invasive pneumococcal disease continues to be a serious risk for patients with sickle cell anemia 12 . Progression of pneumococcal infection in SCD is accelerated by the widespread vascular inflammation which induces expression of endothelial receptors utilized for bacterial invasion 11, 13, 14 . Recent studies have demonstrated pharmacological reduction of vascular inflammation attenuates invasive infection 14 . We sought to determine the impact of administration of hydroxyurea at a dose that reduces leukocytosis 15 on the course of pneumococcal infection.
Since murine sickle cell models lack gamma globin, the model also isolates effects of hydroxyurea independent of HbF induction 15 . We demonstrate that hydroxyurea reduces lung inflammation and confers protection against pneumococcal challenge. Hydroxyurea therapy significantly reduces expression of E-selectin and decreases adhesion and extravasation of neutrophils. The proposed mechanism of protection was confirmed in E-selectin deficient sickle cell mice which showed no additional protective benefit from hydroxyurea therapy. Patients with SCA receiving hydroxyurea therapy were also shown to have significantly reduced serum E-selectin.
This data indicate that hydroxyurea affects leukocyte-endothelial interactions in SCA resulting in protection against lethal pneumococcal sepsis. . Complete blood counts were determined to ascertain the white blood cell number, hematocrit, hemoglobin, and red blood cell distribution were equivalent to the sickle donor.
Transplanted sickle mice were injected with hydroxyurea (50 mg/kg; Sigma) by intraperitoneal route five days per week, starting 10 weeks after transplantation as described 15 . This dosage was chosen based on a maximum tolerated dose experiment with the goal of obtaining a decrease in absolute neutrophil count to 2000-4000, similar to sickle cell patients who typically receive up to 30mg/kg/day during continuous hydroxyurea therapy. A lower dose of 25 mg/kg/day failed to decrease the neutrophil count and was rejected. Only mice demonstrating full engraftment as confirmed by hemoglobin electrophoresis and blood counts at 12 weeks transplantation were used for further studies. Mice were used for experiments after 4 weeks of hydroxyurea administration, at 14 weeks post transplant. For hematoxylin and eosin (H&E) staining tissues were embedded in paraffin, sectioned, and stained as described previously Nikon). One hour prior to surgery, mice were injected intranveneously with TNFα as previously described 14 . GFP neutrophils were prepared as previously described from C57BL/6-Tg(CAG-EGFP)131Osb/LeySopJ mice (Jackson stock #: 006567) 21 . Video images were taken for 5 minutes following injection of GFP neutrophils using NIS Elements (Nikon). The number of adherent neutrophils was measured by an observer unaware of mouse type or treatment group.
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In vivo Two-Photon Imaging. Two-photon laser-scanning microscopy (TPLSM) was performed using an Ultima IV imaging system (Prairie Technologies), a Ti:sapphire Chameleon Ultra femtosecond-pulsed laser (Coherent), and 20× [numerical aperture (NA), 0.95] water-immersion infrared (IR) objectives (Olympus) as previously described 22, 23 . Surgery was performed over the auditory cortex and cranial windows were installed as described above. Rhodamine-dextran (10,000 MW, 1mg/mouse) (Invitrogen) was injected to visualize the vasculature along with the GFP neutrophils.
Samples were excited at 900 nm and consecutive 500 images were captured at a rate of 15 frames/s using the AOD module of the Ultima system.
Measurement of Inflammatory Cytokines.
Inflammatory cytokines were measured using the Milliplex map kits (Millipore) both for murine and human samples. For both samples, CVD kit containing E-selectin, ICAM-1, and VCAM-1 was used.
Mouse Challenge. S. pneumoniae strain D39x was grown on tryptic soy agar (EMD Chemicals) supplemented with 3% sheep blood or defined semisynthetic casein liquid media 24,25 supplemented with 0.5% yeast extract. Hydroxyurea did not effect bacterial growth at concentrations up to 500 μM. Bacterial challenge studies were performed as previously described 26 except that LD50 (rather than LD 100 ) was chosen in order to observe pneumonia as well as sepsis. Bacteria were introduced by intranasal administration in 25 μL saline: 5-8x10 5 CFU for transplanted mice and 2x10 6 CFU for non-transplanted mice. E-selectin mice were challenged with 1x10 6 CFU in 25 μL saline.
Mice were monitored daily for signs of infection and imaged in the IVIS Imaging System 100 Series (Xenogen) 27 . Differences in the survival curves were calculated by Mantel- 
Results

Impact of hydroxyurea on the course of pneumococcal infection
Sickle mice were treated with hydroxyurea for four weeks. Bacteria were administered intranasally to initiate colonization and progression to pneumonia and hydroxyurea was continued daily following challenge. Treatment with hydroxyurea resulted in a significant delay in time to death (Figure 1a 
Effect of hydroxyurea on leukocytes
Consistent with previous studies of hydroxyurea in both patients and murine models, a significant decrease in the number of circulating leukocytes, particularly neutrophils, was observed following hydroxyurea therapy (mean 6.1 vs 4. (Figure 3f, supplementary video 4 ). This indicates that the effect of hydroxyurea in the SCA mice was apparent at the level of neutrophil adherence and margination to endothelia and resulted in decreased pulmonary leukocytosis.
Hydroxyurea decreases E-selectin
A number of host receptors are required for the binding and recruitment of neutrophils to the site of infection including E-selectin and ICAM-1. We sought to determine if any markers of vascular inflammation were altered in sickle mice with or without hydroxyurea therapy. We observed a significant (p<0.001) decrease in the amount of soluble E-selectin in the serum of hydroxyurea treated sickle mice (Figure 4a) but no significant differences in soluble ICAM-1 or VCAM-1 levels between these two groups (Supplementary Figure 2) . Furthermore, we did not observe any significant decreases in the amount of soluble inflammatory cytokines, including TNFα, IL-6, IL-1β, or IL-12 (data not shown). The decreased amount of E-selectin was also observed in the lungs of sickle mice treated with hydroxyurea. Untreated SCA mice displayed high levels of E-selectin on pulmonary epithelia underscoring the heightened pulmonary inflammation (Figure 4c ). Hydroxyurea treatment reduced the amount of E-selectin found throughout the lung in 80% of the animals examined (Figure 4d ), indicating that soluble E-selectin levels correlated well with decreased expression on the cellular surface. No discernible differences were observed for platelet activating factor receptor (PAFr) or P-selectin expression in the lung sections (data not shown).
To ascertain whether hydroxyurea attenuation of E-selectin expression was operative in human SCA patients receiving hydroxyurea therapy, serum samples collected prior to therapy and at MTD were analyzed for levels of soluble E-selectin, For personal use only. on October 28, 2017. by guest www.bloodjournal.org From ICAM-1, and VCAM-1. In excellent agreement with the murine data, we observed a significant (p<0.001) decrease in E-selectin levels following hydroxyurea treatment in patients (Figure 4b) , and no significant differences in either ICAM-1 or VCAM-1 (data not shown).
To confirm that the protective benefit of hydroxyurea in the murine SCA model was indeed dependent upon E-selectin, we next undertook experiments in which Eselectin deficient mice were engrafted with SCA bone marrow, generating an E-selectin deficient SCA mouse. We recognize that E-selectin deficient mice have poor leukocyte recruitment and fail to clear bacteria resulting in increased sensitivity to systemic pneumococcal infection 29, 30 . However, even though the baseline survival is lower in Eselectin deficient mice than in wild type mice (with and without transplant to SCA), improved survival of the SCA E-selectin deficient mice by hydroxyurea would indicate independence from E-selectin. The mice underwent hydroxyurea or saline therapy as described for the mice in Figure 1a and were subsequently challenged with pneumococci. Hydroxyurea was found to confer no significant protective benefit in SCA mice in the absence of E-selectin at either the level of mean time to death, overall survival (Figure 5a ) or bacterial invasion into the blood (Figure 5b ). These data indicate that attenuation of the heightened levels of E-selectin in SCA mice is associated with improved survival. 15, 33 . The lack of HbF in the SCA murine model exposes the HbF-independent effects of hydroxyurea and thus focuses on the benefit of hydroxyurea independent of the spleen. In human patients, the induction of HbF and improved spleen function would potentially add to the protective benefit that we have modeled in the murine system.
Another major player determining the progression of any infection is the leukocyte response. SCA is characterized by a circulating leukocytosis and antiinflammatory strategies that reduce the adhesion of leukocytes improve the microcirculatory pathophysiology of SCA mice 34, 35 . Clinical studies have indicated that cytotoxic agents, such as hydroxyurea, not only increase HbF production, but also decrease leukocytosis due to myelosuppression of the bone marrow 4, 15 . While hydroxyurea reduces the incidence of vaso-occlusive events in SCA 5, 36, 37 , the impact on mortality or rate of infection has not been well characterized. There is a suggestion that patients receiving hydroxyurea therapy may have reduced pulmonary disease 6, 7 . We demonstrate that hydroxyurea not only decreased circulating leukocytosis, but strongly reduced leukocyte recruitment to the infected lung which was associated with significant protection from lung damage, reduced invasion of bacteria into the bloodstream and improved survival from pneumococcal pneumonia in the mouse SCA model. This is consistent with the concept that although leukocytes are required to clear infection, high numbers of leukocytes can damage host tissues and lead to poor outcome despite bacteriological cure 38, 39 .
The possible underlying mechanism for the effect of hydroxyurea on leukocyte recruitment was revealed to involve endothelial leukocyte adhesion molecules. Various 1 6 adhesion molecules, including ICAM-1, VCAM, P-selectin, and E-selectin are elevated in SCA patients 40 . Hydroxyurea specifically decreased the expression of E-selectin on sickle mouse pulmonary epithelial and vascular endothelial cells. This effect was not observed for ICAM-1 or VCAM, similar to previous findings in human SCA patients 41 .
We show that this mechanism was also evident in children with SCA, where hydroxyurea decreased basal leukocytosis and sE-selectin levels in serum. Sickle monocytes induce significantly higher levels of E-selectin in endothelial cells compared to monocytes from healthy controls 42 . Following hydroxyurea therapy in SCA patients 4 as well as in mice, the number of circulating monocytes is reduced consistent with decreased sE-selectin suggesting a potential mechanism for the observations of this study. . Pharmacological targeting of inflammation to alleviate vaso-occlusive complications in SCA has attracted considerable attention 1 7 and numerous therapies have shown great promise 34, [44] [45] [46] . Our data suggest that the decrease in leukocyte adhesion and migration in response to hydroxyurea therapy of SCA attenuates the host inflammatory status independent of HbF expression and has profound beneficial effects on the outcome of pneumococcal pneumonia. The observation that a similar decrease in sE-selectin was observed both in murine and human SCA subjects is encouraging. As multiple approaches for reducing infection risk appear to have distinct mechanisms of action in the SCA host, there exists the exciting possibility that such therapies may have an additive effect and further reduce susceptibility to infection 11, 14 . Mean vascular lesion scores of SCA and mock transplanted mice receiving hydroxyurea or saline therapy at 24 hours post challenge (n=5/group). f) Quantification of the signs of interstitial pneumonia determined by histological examination of lung sections at 24 hours post infection (n=5 mice/group; mean=3.7 ± 0.5 for SCA saline, 2.6 ± 0.4 for SCA hydroxyurea). *=statistically significant p<0.05 compared to SCA, †=statistically significant p<0.05 compared to SCA+ hydroxyurea using Mann-Whitney. Figure 3 . Hydroxyurea attenuates neutrophil adhesion and migration. a) Neutrophil recruitment to the lung in response to killed pneumococci administered intratracheally was quantitated by FACS of bronchoalveolar lavage from saline and hydroxyurea treated SCA mice 6 hours following challenge (n = 6 mice per group; PBS 26.2 ± 16.8, hydroxyurea =5.16 ± 3.00; *=statistically significant compared to SCA p<0.05 by Mann Whitney). Data represents percentage of total cells isolated from BAL. b) SCA mice ± hydroxyurea were exposed to intravenous TNFα to induce endothelial activation and neutrophil margination. Neutrophil adherence was quantitated in cranial windows (5 minutes at 40X per mouse for at least 4 mice per group; *=statistically significant compared to SCA p<0.05 by Mann Whitney). c,d) Representative images through cranial windows on SCA (c) or SCA+ hydroxyurea (d) mice. Neutrophils indicated by arrows, 10x magnification. (e,f) Representative images of GFP neutrophils (green) imaged by two-photon microscopy in the rhodamine dextran labeled vasculature (red) of SCA mice (e) and SCA mice treated with hydroxyurea (f). For personal use only. on October 28, 2017. by guest www.bloodjournal.org From 145 +/-45 ng/mL, SCA hydroxyurea n=35, mean= 98.5 +/-35.5 ng/mL)) and (b) humans (SCA/pre-hydroxyurea, n=92, mean=77 +/-60, SCA/MTD n=57, mean=31 +/-26, healthy controls n=18, mean=22 +/-14) undergoing hydroxyurea therapy. All groups significantly different (p<0.001) from all other groups by two-tailed T-test (*=compared to SCD mock, †=compared to SCD hydroxyurea). (c-e): Representative sections of lung stained for E-selectin (purple) from SCA animals receiving saline (c), hydroxyurea (d), or a negative control with no primary antibody (e). Left column: 4X and Right column: 10X magnification. Figure 5 . Lack of effect of hydroxyurea on pneumococcal pneumonia in E-selectin deficient SCA mice. a) Mean overall survival of E-selectin deficient (triangles, n=9), Eselectin deficient/SCA mice treated with saline (circles, n=21), and E-selectin deficient/SCA mice treated with hydroxyurea (squares, n=18). Mice were challenged with 3x10 6 CFU in 25 μL saline. No significant difference (p=0.744, Mantel-Cox log rank test) was observed between the E-selectin deficient/SCA mice untreated versus treated with hydroxyurea. b) Log CFU/ml of bacteria in blood of mice in panel a at 24 hours post challenge. Each symbol is a mouse and bar is mean. ----is limit of detection; *= statistically significant difference compared to SCA saline group, p=0.03 for survival, p=0.003 for blood titers.
